Latest Breaking News On - Prnewswire precigen inc - Page 4 : vimarsana.com

Precigen Reports First Quarter 2022 Financial Results and Business Updates

– Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly...

Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference

Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference

Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares News provided by Share this article Share this article GERMANTOWN, Md., Jan. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 17,250,000 shares of its common stock at a public offering price of $7.50 per share, including the exercise in full by the underwriters of their option to purchase an additional 2,250,000 shares of common stock. Gross proceeds to Precigen from the offering were approximately $129.4 million before deducting the underwriting discount and other offering expenses payable by Precigen.

Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock

Share this article Share this article GERMANTOWN, Md., Jan. 22, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $112.5 million, excluding any exercise of the underwriters' option. The offering is expected to close on January 26, 2021, subject to customary closing conditions. Wells Fargo Securities and Stifel are acting as joint book-running managers for the offering with JMP Securities acting as lead manager and H.C. Wainwright & Co. acting as co-manager.